about
Natalizumab for relapsing remitting multiple sclerosisExploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisJC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's DiseaseNatalizumab in Multiple Sclerosis: Long-Term Management.Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV ReactivationCD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.Treating multiple sclerosis with natalizumab.Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.Efficiency of antibody therapy in demyelinating diseases.Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis.[Guidelines for vaccination of immunocompromised individuals].The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.Peripherally derived T regulatory and γδ T cells have opposing roles in the pathogenesis of intractable pediatric epilepsy.The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.ZSTK474, a novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.
P2860
Q24235861-C9220108-D5BF-40CA-8F1B-356258A1ACB3Q26770818-DEFA2AA7-6B2D-434C-BAFB-704B3D359071Q26852060-F38C02A3-2532-45FC-B9D4-3FC6FB0B2331Q28538974-97DE8288-B04A-4BFC-B1C8-4D7A48404195Q33754882-B026080A-FACA-4174-82EE-20B8D4ABCB8CQ36093592-89CAAA69-2901-4096-A597-DEC7D60F2FAEQ36645170-089FDE37-7A92-4A05-8805-7A9BF0DF5427Q37957123-86BAA86C-2068-407B-8488-C74079FDCF6DQ38097527-D75B2F3D-5809-4AEE-95C7-D117CFC09BBFQ38842554-1175DCF9-FC31-4972-B44F-B971B515B082Q39188128-98CF6A49-925A-4B6C-82A2-E2D81F104C9DQ40045794-A194013D-510E-4B19-9198-72E848D98797Q40466907-E5EAF5AF-7A7F-4812-9897-8A9AD9BCD751Q40600058-363A5B07-C9B5-46E4-B738-CD7401E01E92Q45901439-C9F38E4A-25EA-4A8F-857F-1BE1250DC91DQ50533963-9A3E3AD3-D227-4171-8165-C984662F1FFEQ53998964-C60752C9-DBC2-4395-B266-A1E161140A21Q54351297-6E7651B1-1758-4FD0-945F-AC3B89F1E194
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Natalizumab in the treatment of multiple sclerosis
@ast
Natalizumab in the treatment of multiple sclerosis
@en
Natalizumab in the treatment of multiple sclerosis
@nl
type
label
Natalizumab in the treatment of multiple sclerosis
@ast
Natalizumab in the treatment of multiple sclerosis
@en
Natalizumab in the treatment of multiple sclerosis
@nl
prefLabel
Natalizumab in the treatment of multiple sclerosis
@ast
Natalizumab in the treatment of multiple sclerosis
@en
Natalizumab in the treatment of multiple sclerosis
@nl
P2860
P356
P1476
Natalizumab in the treatment of multiple sclerosis
@en
P2093
Norman Putzki
Ozgür Yaldizli
P2860
P304
P356
10.1177/1756285608101861
P577
2009-03-01T00:00:00Z